ClinicalTrials.gg
CompletedNCT02421679P202Updated Feb 6, 2025Results posted

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

A Phase 2 interventional study of TNX-102 SL in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
334th of 1,491
159 · median 65
Started
2015
with 58 others
Phase 2
168 of 1,664
38 open now
Registered
614th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 334th largest by enrollment of the 1,491 interventional ones that give a count, is one of 59 that started in 2015, is one of 168 in phase 2, and was the 614th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition. Patients recruited into this trial are those who have successfully completed the double-blind study, TNX-CY-P201 (AtEase Study) [NCT02277704]. Patients will not be made aware of the therapy they received during the double-blind study.

Read the detailed description

The study will consist of 4 clinic visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same date as the final visit in the lead-in P201 study) and visits after 2, 6 and 12 weeks of treatment. The previous requirements in the lead-in study for refraining from the use of certain concomitant medications and trauma-focused psychotherapies will be relaxed. Patients may continue to take rescue therapy for sleep, as appropriate, or they may utilize other medications as needed to help them sleep, per the judgment of the investigator.

Eligible patients who provide written informed consent will take one TNX-102 SL tablet daily at bedtime sublingually (under the tongue) for 12 weeks. All patients will be assigned to receive tthe same dosage of TNX-102 SL, regardless of their treatment assignment in the lead-in study. No patients, investigators, or study staff will know the assigned study treatment from the lead-in study, P201, at the time of entry into the extension study. Patient data collected at the Week 12 visit (Visit 9) in the lead-in P201 study will be used as one of the baseline values for this study.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • Military-related PTSD and other related conditions
  • open-label extension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the lead-in study and is judged as reasonably compliant, with at least 60% compliance
  • Signed
  • Met all prior inclusion and exclusion requirements for lead-in study
  • No new or worsening medical conditions since starting the lead-in study that could pose a safety risk or interfere with participation in the study
  • Willing to refrain from use of specific medication (ask PI)
  • Female patients of continue to practice medically acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    TNX-102 SL

    TNX-102 SL taken daily at bedtime for 12 weeks

    Drug: TNX-102 SL

Interventions

  • 1x 2.8mg TNX-102 SL Sublingual tablet

    Also known as: cyclobenzaprine HCI

06

What researchers measure

Primary outcomes

  1. Newly Treatment Emergent Adverse Events

    Number of patients with new treatment emergent AEs since completing lead-in study

    Time frame: Week 12

Secondary outcomes

  1. Total CAPS-5 (Clinician Administered PTSD Scale (for Diagnostic and Statistical Manual of Mental Disorders Version 5)

    Changes in total CAPS-5 score from baseline in lead-in study and since baseline in this study. CAPS-5 score ranges from 0-80 with lower scores indicating less sever PTSD symptoms.

    Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12

  2. Response Rates a in Total CAPS-5 Score

    ≥30% decrease in Total CAPS-5 score from baseline in lead-in study and since baseline in this study. Lower scores on CAPS-5 indicate less severe PTSD symptoms.

    Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P201 Week 12

  3. CAPS-5 Cluster Score Items

    Changes from baseline in lead-in study and since baseline in this study in item scores, including * intrusion symptoms (Criterion B) - Score ranges from 0 to 20. * CAPS-5 item 2. (B-2) (unpleasant dreams related to the trauma) - Score ranges from 0 to 4 * persistent avoidance (Criterion C) - Score ranges from 0 to 8 * negative cognitions and mood (Criterion D) - Score ranges from 0 to 28 * arousal and reactivity (Criterion E) - Score ranges from 0 to 24 Lower scores indicate less severe symptoms on all items

    Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12

  4. Montgomery-Asberg Depression Rating Scale

    Changes from baseline in lead-in study and since baseline in this study in MADRS. Score ranges from 0 to 60. Lower scores indicate less severe depression symptoms.

    Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12

  5. PROMIS (Patient -Reported Outcome Measurement Information System)

    Changes from baseline in lead-in study and since baseline in this study in PROMIS scores. Raw scores are converted to T-scores with mean of 50 and standard deviation of 10 using published conversion tables based on the US population. * Fatigue T-score ranges from 33.1 to 77.8. Lower scores indicate less fatigue * Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance * Global Physical Health T-score ranges from 16.2 to 67.7. Lower scores indicate better physical health * Global Mental Health T-score ranges from 21.2 to 67.6. Lower scores indicate better mental health

    Time frame: P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12

07

Results

Posted Feb 6, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Started586437
Completed474932
Not completed11155

Outcome measures

PrimaryNewly Treatment Emergent Adverse Events

Number of patients with new treatment emergent AEs since completing lead-in study

Time frame:
Week 12
Reported as:
Count of participants · Participants
Newly Treatment Emergent Adverse Events
ParticipantsPlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Newly Treatment Emergent Adverse Events372014
SecondaryTotal CAPS-5 (Clinician Administered PTSD Scale (for Diagnostic and Statistical Manual of Mental Disorders Version 5)

Changes in total CAPS-5 score from baseline in lead-in study and since baseline in this study. CAPS-5 score ranges from 0-80 with lower scores indicating less sever PTSD symptoms.

Time frame:
P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Reported as:
Least squares mean · units on a scale
Total CAPS-5 (Clinician Administered PTSD Scale (for Diagnostic and Statistical Manual of Mental Disorders Version 5)
units on a scalePlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Change from P201 Baseline to P202 Week 12-25.3 ± 2.55-25.6 ± 2.59-26.9 ± 2.80
Change from P202 Baseline to P202 Week 12-4.9 ± 1.80-4.8 ± 1.82-3.7 ± 2.01
SecondaryResponse Rates a in Total CAPS-5 Score

≥30% decrease in Total CAPS-5 score from baseline in lead-in study and since baseline in this study. Lower scores on CAPS-5 indicate less severe PTSD symptoms.

Time frame:
P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P201 Week 12
Reported as:
Count of participants · Participants
Response Rates a in Total CAPS-5 Score
ParticipantsPlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Patients with ≥30% decrease in Total CAPS-5 score from P201 Day 1 to P202 Week 12434730
Patients with ≥30% decrease in Total CAPS-5 score from P202 Day 1 to P202 Week 12202413
SecondaryCAPS-5 Cluster Score Items

Changes from baseline in lead-in study and since baseline in this study in item scores, including * intrusion symptoms (Criterion B) - Score ranges from 0 to 20. * CAPS-5 item 2. (B-2) (unpleasant dreams related to the trauma) - Score ranges from 0 to 4 * persistent avoidance (Criterion C) - Score ranges from 0 to 8 * negative cognitions and mood (Criterion D) - Score ranges from 0 to 28 * arousal and reactivity (Criterion E) - Score ranges from 0 to 24 Lower scores indicate less severe symptoms on all items

Time frame:
P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Reported as:
Least squares mean · units on a scale
CAPS-5 Cluster Score Items
units on a scalePlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Change from P201 Day 1 to P202 Week 12 in Criterion B-7.7 ± 0.82-7.4 ± 0.82-7.7 ± 0.91
Change from P202 Day 1 to P202 Week 12 in Criterion B-1.9 ± 0.66-1.5 ± 0.66-1.4 ± 0.74
Change from P201 Day 1 to P202 Week 12 in Item B-2-1.3 ± 0.23-1.4 ± 0.24-1.4 ± 0.26
Change from P202 Day 1 to P202 Week 12 in Item B-2-0.3 ± 0.20-0.4 ± 0.21-0.2 ± 0.23
Change from P201 Day 1 to P202 Week 12 in Criterion C-3.1 ± 0.45-3.2 ± 0.45-3.1 ± 0.50
Change from P202 Day 1 to P202 Week 12 in Criterion C-0.4 ± 0.38-0.5 ± 0.39-0.5 ± 0.42
Change from P201 Day 1 to P202 Week 12 in Criterion D-7.6 ± 1.10-8.4 ± 1.12-9.1 ± 1.22
Change from P202 Day 1 to P202 Week 12 in Criterion D-1.1 ± 0.85-1.8 ± 0.85-1.4 ± 0.95
Change from P201 Day 1 to P202 Week 12 in Criterion E-6.8 ± 0.83-6.4 ± 0.84-7.1 ± 0.91
Change from P202 Day 1 to P202 Week 12 in Criterion E-1.4 ± 0.62-0.9 ± 0.62-0.8 ± 0.69
SecondaryMontgomery-Asberg Depression Rating Scale

Changes from baseline in lead-in study and since baseline in this study in MADRS. Score ranges from 0 to 60. Lower scores indicate less severe depression symptoms.

Time frame:
P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Reported as:
Least squares mean · units on a scale
Montgomery-Asberg Depression Rating Scale
units on a scalePlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Change from P201 Day 1 to P202 Week 12-8.1 ± 1.53-9.3 ± 1.57-9.9 ± 1.66
Change from P202 Day 1 to P202 Week 120.1 ± 1.28-1.1 ± 1.30-2.1 ± 1.40
SecondaryPROMIS (Patient -Reported Outcome Measurement Information System)

Changes from baseline in lead-in study and since baseline in this study in PROMIS scores. Raw scores are converted to T-scores with mean of 50 and standard deviation of 10 using published conversion tables based on the US population. * Fatigue T-score ranges from 33.1 to 77.8. Lower scores indicate less fatigue * Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance * Global Physical Health T-score ranges from 16.2 to 67.7. Lower scores indicate better physical health * Global Mental Health T-score ranges from 21.2 to 67.6. Lower scores indicate better mental health

Time frame:
P201 Day 1 (12 weeks prior to P202 Day 1), P202 Day 1, P202 Week 12
Reported as:
Least squares mean · T-score
PROMIS (Patient -Reported Outcome Measurement Information System)
T-scorePlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Change from P201 Day 1 to P202 Week 12 in PROMIS Sleep Disturbance T-scores-10.4 ± 2.50-12.2 ± 2.58-14.3 ± 2.75
Change from P202 Day 1 to P202 Week 12 in PROMIS Sleep Disturbance T-scores0.7 ± 2.360.4 ± 2.40-3.1 ± 2.60
Change from P201 Day 1 to P202 Week 12 in PROMIS Fatigue T-scores-5.6 ± 2.05-6.4 ± 2.08-8.0 ± 2.26
Change from P202 Day 1 to P202 Week 12 in PROMIS Fatigue T-scores0.9 ± 1.781.1 ± 1.79-0.4 ± 1.93
Change from P201 Day 1 to P202 Week 12 in PROMIS Global Mental Health T-scores7.1 ± 1.767.1 ± 1.7910.1 ± 1.95
Change from P202 Day 1 to P202 Week 12 in PROMIS Global Mental Health T-scores0.5 ± 1.500.2 ± 1.531.8 ± 1.67
Change from P201 Day 1 to P202 Week 12 in PROMIS Global Physical Health T-scores3.1 ± 1.503.2 ± 1.535.8 ± 1.66
Change from P202 Day 1 to P202 Week 12 in PROMIS Global Physical Health T-scores-0.7 ± 1.18-0.2 ± 1.201.7 ± 1.30

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo- TNX-102 SL 2.8 mg0/54 (0%)0/54 (0%)29/54 (53.7%)
TNX 102 SL 2.8 mg - TNX-102 SL 2.8 mg0/60 (0%)0/60 (0%)7/60 (11.7%)
TNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg0/35 (0%)0/35 (0%)3/35 (8.6%)
Most frequent other events
Most frequent other events
EventPlacebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mg
Hypoaesthesia OralGastrointestinal disorders22/543/602/35
Paraesthesia OralGastrointestinal disorders9/541/600/35
Product Taste AbnormalProduct Issues3/540/600/35
SomnolenceNervous system disorders2/543/601/35

Baseline characteristics

Numbers are only reported for the safety population, which includes all patients who received at least one dose of investigational product under this protocol.

Age, Continuous
Age, Continuous(years)Placebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mgTotal
Mean33.1 ± 7.0035.8 ± 8.2235.4 ± 9.2734.7 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)Placebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mgTotal
Female43310
Male505732139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mgTotal
Hispanic or Latino118524
Not Hispanic or Latino435230125
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mgTotal
American Indian or Alaska Native0101
Asian3104
Native Hawaiian or Other Pacific Islander0000
Black or African American916833
White364125102
More than one race2002
Unknown or Not Reported4127
Region of Enrollment
Region of Enrollment(participants)Placebo- TNX-102 SL 2.8 mgTNX 102 SL 2.8 mg - TNX-102 SL 2.8 mgTNX-102 SL 5.6 mg - TNX-102 SL 2.8 mgTotal
United States546035149
08

Study locations

22 sites
  • Tuscaloosa VA Medical Center
    Tuscaloosa, Alabama 35404, United States
  • Noesis Pharma
    Phoenix, Arizona 85032, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Synergy Clinical Research
    National City, California 91950, United States
  • Excell Research, Inc
    Oceanside, California 92506, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • CITRIALS
    Riverside, California 92506, United States
  • CESAMH
    San Diego, California 92103, United States
  • Cns, Inc.
    Torrance, California 90502, United States
  • Sarkis Clinical Trials
    Lake City, Florida 32025, United States
  • Compass Research North, LLC
    Leesburg, Florida 34748, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Atlanta Center For Medical Research
    Atlanta, Georgia 30308, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Novex Clinical Research
    New Bedford, Massachusetts 02740, United States
  • Premier Psychiatric Research Institute, Inc.
    Lincoln, Nebraska 68526, United States
  • Altea Research
    Las Vegas, Nevada 89102, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in May 2016, 13 months.

Results were first posted in Feb 2025, 8 years 8 months after primary completion. A results delay was requested in Oct 2017.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2015
First posted
Apr 21, 2015
StartActual
Apr 14, 2015
Primary completionActual
May 26, 2016
CompletionActual
May 26, 2016
Results delay requested
Oct 26, 2017
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02421679
Responsible party
Sponsor
First posted
Apr 21, 2015
Start date
Apr 14, 2015
Primary completion
May 26, 2016
Completion
May 26, 2016
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Study contacts

Denise Bedoya
study director · Premier Research Group plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion